Source-grounded facts extracted from Tvardi Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $6.8 million, EPS $(0.73).
“Net loss for the three months ended March 31, 2026, was $6.8 million, as compared to a net loss of $9.6 million for the comparable period in 2025. Basic and diluted net loss per share attributable to common shareholders for the three months ended March 31, 2026, were a net loss of $(0.73), compared to a net loss of $(3.72) for the comparable period in 2025.”
Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.
“On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.”
Cynthia Smith was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Imran Alibhai, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Shaheen Wirk, M.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Wallace Hall was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Michael Wyzga was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Sujal Shah was appointed as Director and Chair of the Board at Tvardi Therapeutics, Inc..
“Sujal Shah was appointed to the Company’s board of directors and as Chair of our board of directors upon the closing of the Merger.”
Susan Shiff, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Lisa von Moltke, M.D. resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Jeffrey Ives, Ph.D. resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Helen M. Boudreau resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Christopher Posner resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Martin Vogelbaum resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.
“or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue”
Joana Goncalves resigned as Chief Medical Officer at Tvardi Therapeutics, Inc..
“On March 19, 2024, Dr. Joana Goncalves, the Chief Medical Officer of Cara Therapeutics, Inc. (the “Company”), informed the Company of her intention to resign from her role effective April 16, 2024, to pursue another opportunity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.